BriaCell Therapeutics Announces Pricing of Offering

Executive Summary

• BriaCell Therapeutics announced the pricing of a best-efforts public offering of 1,449,300 common shares, raising approximately $4.7 million in gross proceeds.
• The shares were priced at $3.25 per share, with ThinkEquity serving as the sole placement agent.
• Net proceeds from the offering will be allocated to working capital, general corporate purposes, and the advancement of business objectives.

Key Details

• Offering Structure: Best-efforts public offering of common shares conducted under an effective Form S-3 shelf registration statement filed with the SEC.
• Share Quantity & Price: 1,449,300 common shares priced at $3.25 per share.
• Gross Proceeds: Approximately $4.7 million (prior to deducting placement agent fees and other offering expenses).
• Expected Closing: June 2, 2026, subject to satisfaction of customary closing conditions.
• Use of Proceeds: Working capital requirements, general corporate purposes, and advancement of business objectives.
• Placement Agent: ThinkEquity acting as sole placement agent for the offering.
• Exchange/Regulatory Notes: The Company is relying on TSX Section 602.1 exemption regarding eligible interlisted issuers on a recognized exchange (Nasdaq). A final prospectus supplement and accompanying prospectus will be filed with the SEC.